XP Chemistries AB is a Sweden-based chemical, biological and pharmaceutical manufacturer. The Company has an international patent portfolio covering sustainable nature-inspired technologies optimal combinations of catalytic processes for the production of bio-based chemicals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/07/26	SEK 0.1600	-3.32%	32,197
15/07/26	SEK 0.1655	0.00%	177,693
14/07/26	SEK 0.1655	+1.22%	19,307
13/07/26	SEK 0.1635	+0.62%	114,543
10/07/26	SEK 0.1625	-0.61%	208,836

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Delayed Nasdaq Stockholm Other stock markets 15:29:19 16/07/2026 BST			5-day change	1st Jan Change
0.1600 ^SEK	-3.32%		-2.14%	-10.86%

05-22	XP Chemistries reports Q1 operating profit of SEK -3.07 mln	RE
05-22	XP Chemistries AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	51.96M 5.4M 4.72M 4.35M 4M 7.58M 519M 7.71M 20.39M 254M 20.27M 19.82M 875M	P/E 2024	-1.48x	P/E 2025	-5.22x
Enterprise Value	36.74M 3.82M 3.34M 3.08M 2.83M 5.36M 367M 5.45M 14.41M 179M 14.33M 14.01M 618M	EV / Sales 2024	43.7x	EV / Sales 2025	126x
Free-Float	42.26%	Yield 2024 *	-	Yield 2025	-

05-22	XP Chemistries reports Q1 operating profit of SEK -3.07 mln	RE
05-22	XP Chemistries AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Xp Chemistries receives patent in Japan	RE
02-19	XP Chemistries Q4 operating loss SEK 3.3 mln	RE
02-19	XP Chemistries AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
12-16	XP Chemistries signs loi with European distributor for launch of capsaicin for animal feed	RE
11-20	XP Chemistries Q3 operating loss SEK 2.6 mln	RE
11-20	XP Chemistries AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
26/08/25	XP Chemistries AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
26/08/25	XP Chemistries Q2 operating loss SEK 4.6 mln	RE
10/07/25	XP Chemistries decides on directed share issue	RE
16/05/25	XP Chemistries AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/04/25	Xp Chemistries Says EFSA Gives Green Light To Capsaicin As Animal Feed Supplement	RE

1 day	-3.32%
1 week	-2.14%
Current month	-5.60%
1 month	-8.83%
3 months	-9.86%
6 months	-13.04%
Current year	-10.86%

XP Chemistries AB Share Price

Stocks

XPC

SE0016787279

Pharmaceuticals

Valuation: XP Chemistries AB

Chart: XP Chemistries AB

Latest news : XP Chemistries AB

Quotes and Performance

Course Extremes

Managers and Directors: XP Chemistries AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	0.15	0.17
1 month	0.15	0.18
Current year	0.15	0.2
1 year	0.15	0.33
3 years	0.03	0.58
5 years	0.03	4.5
10 years	0.03	4.5

Manager	Title	Age	Since
Erik Nelsson CEO	Chief Executive Officer	43	31/12/2020
Anders Frejdh DFI	Director of Finance/CFO	52	31/12/2020
Shuang Zheng Lin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Armando Córdova CHM	Chairman	56	31/12/2014
Samson Afewerki BRD	Director/Board Member	41	31/12/2014
Anna Svantes BRD	Director/Board Member	35	31/12/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/04/24	Erik Nelsson	Buy	Chief Executive Officer	30,000	0.0204%
14/04/24	Erik Nelsson	Buy	Chief Executive Officer	20,000	0.0136%
14/04/24	Erik Nelsson	Buy	Chief Executive Officer	30,000	0.0204%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XP CHEMISTRIES AB	-3.32%	-2.14%	-47.71%	-68.63%	5.4M
ELI LILLY AND COMPANY	+2.54%	-2.75%	+49.85%	+164.68%	1,031B
JOHNSON & JOHNSON	+1.03%	-3.24%	+52.14%	+57.60%	595B
ABBVIE INC.	+2.85%	+0.81%	+32.20%	+86.86%	431B
ROCHE HOLDING AG	-0.03%	-1.49%	+29.00%	+23.23%	326B
NOVARTIS AG	+0.84%	-0.93%	+29.46%	+45.01%	277B
ASTRAZENECA PLC	+0.55%	-5.61%	+20.79%	+23.58%	263B
NOVO NORDISK A/S	+1.59%	+4.89%	-22.56%	-37.35%	224B
AMGEN INC.	+2.70%	+1.28%	+23.16%	+61.64%	193B
GILEAD SCIENCES, INC.	+0.98%	-1.28%	+21.17%	+71.80%	164B
Average	+1.00%	-3.47%	+18.75%	+42.84%	350.43B
Weighted average by Cap.	+1.70%	-4.31%	+34.90%	+80.79%

	2024	2025
Net sales	284K 29.49K 25.78K 23.78K 21.86K 41.43K 2.84M 42.13K 111K 1.39M 111K 108K 4.78M	327K 34K 29.73K 27.42K 25.21K 47.77K 3.27M 48.58K 128K 1.6M 128K 125K 5.51M
Net income	-7.13M -741K -648K -598K -549K -1.04M -71.29M -1.06M -2.8M -34.84M -2.78M -2.72M -120M	-8.52M -885K -774K -714K -656K -1.24M -85.15M -1.26M -3.34M -41.62M -3.32M -3.25M -143M
Net Debt	-2.15M -223K -195K -180K -165K -313K -21.44M -318K -842K -10.48M -837K -818K -36.12M	-15.23M -1.58M -1.38M -1.28M -1.17M -2.22M -152M -2.26M -5.97M -74.37M -5.94M -5.81M -256M